Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: a phase 3, randomized controlled trial

This is a RCT study (also classified as: Phase 3).

August 1, 2025Journal of InfectionOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Recombinant zoster vaccine effectively prevents herpes zoster recurrence in older adults with prior infection, showing significant results.
In a randomized controlled trial, none of the confirmed recurrence cases occurred in vaccine recipients, achieving non-inferiority for safety and efficacy.
Participants receiving the recombinant zoster vaccine displayed robust immune responses, indicating strong immunogenicity in this demographic.
Safety assessments revealed no significant safety signals, supporting the continued use of the recombinant zoster vaccine among older populations.

We only have this paper's title and publication details.

Phase 3 trial finds recombinant zoster vaccine effectively prevents herpes zoster recurrence in adults, suggesting a significant safety profile.

No takes yet. Share an insight, caveat, or question.

Jegede et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share